Trial · NCT00519285
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival Time | Placebo | 21.22 | 95% Confidence Interval 19.614 to 23.754 | months | |
| Overall Survival Time | Aflibercept | 22.14 | 95% Confidence Interval 20.304 to 24.082 | months | |
| Prostate Specific Antigen Response Rate | Placebo | 63.5 | 95% Confidence Interval 59.5 to 67.5 | percentage of participants | |
| Prostate Specific Antigen Response Rate | Aflibercept | 68.6 | 95% Confidence Interval 64.7 to 72.4 | percentage of participants | |
| Time to Skeletal Related Events | Placebo | 14.98 | 95% Confidence Interval 13.733 to 16.427 | months | |
| Time to Skeletal Related Events | Aflibercept | 15.31 | 95% Confidence Interval 14.127 to 16.657 | months | |
| Progression Free Survival Time | Placebo | 6.24 | 95% Confidence Interval 5.585 to 6.899 | months | |
| Progression Free Survival Time | Aflibercept | 6.90 | 95% Confidence Interval 6.209 to 7.359 | months | |
| Tumor Response Rate in Participants With Measurable Disease | Placebo | 28.1 | 95% Confidence Interval 23.2 to 33.1 | percentage of participants | |
| Tumor Response Rate in Participants With Measurable Disease | Aflibercept | 38.7 | 95% Confidence Interval 33.4 to 44.0 | percentage of participants | |
| Prostate Specific Antigen Progression-free Survival Time | Placebo | 8.11 | 95% Confidence Interval 7.622 to 8.575 | months | |
| Prostate Specific Antigen Progression-free Survival Time | Aflibercept | 8.25 | 95% Confidence Interval 7.819 to 8.772 | months | |
| Pain Progression-free Survival Time | Placebo | 9.72 | 95% Confidence Interval 8.509 to 11.499 | months | |
| Pain Progression-free Survival Time | Aflibercept | 9.20 | 95% Confidence Interval 8.181 to 10.448 | months | |
| Pain Response Rate | Placebo | 46.3 | 95% Confidence Interval 34.3 to 58.2 | percentage of participants | |
| Pain Response Rate | Aflibercept | 35.8 | 95% Confidence Interval 24.3 to 47.3 | percentage of participants | |
| Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life | Placebo | Change from baseline at cycle 1 (n =493, 461) | 5.08 | Standard Deviation 12.73 | units on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life | Aflibercept | Change from baseline at cycle 1 (n =493, 461) | 1.30 | Standard Deviation 15.70 | units on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life | Placebo | Change from baseline at cycle 2 (n =467, 437) | 6.22 | Standard Deviation 14.50 | units on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life | Aflibercept | Change from baseline at cycle 2 (n =467, 437) | -0.03 | Standard Deviation 17.99 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00519285/results